MAPT and supranuclear palsy, progressive, 1: To assess the contribution of APOE genotype to PSP and CBD susceptibility in the absence of the strong MAPT H1 genetic risk factor, we examined the aforementioned associations when excluding individuals who were homozygous for that MAPT H1/H1 genotype (Table 2).